A Phase 2, Double-blind, Placebo-controlled Multicenter Study to Determine the Efficacy and Safety of Luspatercept (ACE-536) in Adults With Non Transfusion Dependent Beta (β)-Thalassemia
Not yet recruiting
Phase of Trial: Phase II
Latest Information Update: 28 Nov 2017
At a glance
- Drugs Luspatercept (Primary)
- Indications Beta-thalassaemia
- Focus Therapeutic Use
- Acronyms BEYOND
- Sponsors Celgene Corporation
- 09 Nov 2017 Status changed from planning to not yet recruiting.
- 12 Jan 2017 New trial record
- 06 Jan 2017 According to an Acceleron Pharma media release, the company plans to initiate this trial by the end of this year.